PAGE 06: WHERE EACH FACT CAME FROM
Every BPC-157 source in one list
You can open the animal studies and human reports. FDA pages and reviews are here too. Each entry takes you to the source.
What you will find in the BPC-157 references
Use this page to check a claim. You can open every study and FDA page used here. Each entry has a link for more reading.
The early papers cover rat tendons and stomach sores. A 2017 paper follows new blood vessel growth. A 2022 paper tells how quickly the drug left rats and dogs.
Only three small reports included people. You can also read papers that review the animal work. FDA pages give the dates and pharmacy rules.
A bracketed number beside a claim points here. The same number always leads to the same source. You don't have to trust a short summary alone.
Nothing on this page tells you to obtain BPC-157. Nobody sells it here. This page is only a reading list.
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
- He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
- Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-1037. ↗
- Novinscak T, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008;38(8):716-725. ↗
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines. 2022;10(12):3221. ↗
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. ↗
- McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. (Human-data context throughout; concludes BPC-157 is investigational with only three small human pilots.) See also Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025 (PMID 40131143); and Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024 (PMID 39325560). ↗
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar. (Lists BPC-157, KPV, TB-500, and MOTs-C as bulk drug substances being considered for inclusion on the 503A Bulks List; a scheduled discussion, not a decision.) ↗
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Definitions of Category 1 and Category 2; the bulks-list and PCAC framework; the January 7, 2025 change to categorizing newly nominated substances.) ↗
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (Category 2 entries for 'BPC-157 (free base)' and 'BPC-157 acetate'; FDA's stated safety rationale; effective with the September 29, 2023 update.) ↗
- U.S. Food and Drug Administration. Human Drug Compounding — sections 503A and 503B framework and the lawful access pathway (licensed-prescriber evaluation, valid patient-specific prescription, 503A compounding pharmacy or 503B outsourcing facility; ingredient-eligibility requirement; telehealth as a front-end consultation channel only). ↗
- Author group (2025) BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025. 18:1450. ↗
- Tohyama Y, et al. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyltryptophan autoradiographic measurements. Life Sci. 2004. 76:345-357. ↗
- Boban Blagaic A, et al. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol. 2005. 512:173-179. ↗
- Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. 19:19066-19077. ↗